article thumbnail

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.

Vaccines 110
article thumbnail

FDA panel backs bluebird’s CALD gene therapy, despite safety worries

pharmaphorum

The FDA may have safety concerns abut bluebird bio’s gene therapy for rare, fatal disease cerebral adrenoleukodystrophy (CALD), but its advisors believe its benefits far outweigh the risks. The post FDA panel backs bluebird’s CALD gene therapy, despite safety worries appeared first on.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What’s the best time to take ashwagandha?

The Checkup by Singlecare

Others take ashwagandha to improve cognitive function or boost the immune system. Food and Drug Administration (FDA), there is no official guidance on how much to take. In the documented reports, the signs of acute liver injury included jaundice, nausea, lethargy, pruritus, abdominal discomfort, and hyperbilirubinemia.

article thumbnail

EU says not enough evidence to warrant fourth COVID jabs

pharmaphorum

The official word from the EU authorities is that for now a fourth dose of Pfizer/BioNTech’s Comirnaty or Moderna’s SpikeVax – the preferred booster vaccines in Europe – should only be used in adults aged 80 years and over and people with compromised immunity. FDA gives first thinking on updating vaccines.

article thumbnail

US experts stress over safety of AZ’s COVID-19 vaccine

pharmaphorum

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine trial could compromise the whole project, as the FDA weighs whether to give the go ahead for US studies to resume.

Vaccines 105
article thumbnail

US panel backs Omicron-targeting vaccines for booster campaigns

pharmaphorum

Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). Pfizer and BioNTech’s updated shot – also targeting the wild-type virus and BA.1

article thumbnail

Scientists make case for one dose of Pfizer’s COVID jab to stretch supplies

pharmaphorum

The scientists draw their conclusions from an analysis of documents submitted to the FDA, which indicate 52% protection with the Comirnaty (BNT162b2) vaccine after a dose. That was measured two weeks after dosing however, and they argue that isn’t enough time for the immune system to full respond to the jab.